This study is designed to compare the effectiveness of different treatment combinations for people with Colorectal Cancer that has not been treated before, cannot be removed by surgery, or has spread to other parts of the body. The research focuses on comparing a combination involving the drug pumitamig, also known as BNT327, with a standard treatment combination that includes bevacizumab.
The treatment groups will receive various medications. One group will receive a combination of pumitamig with several chemotherapy drugs, including oxaliplatin, calcium folinate, fluorouracil, irinotecan hydrochloride trihydrate, and capecitabine. These drugs are administered through different methods, such as an infusion, which is a liquid medicine delivered directly into a vein, or by oral use, which means taking the medicine by mouth. The other group will receive a combination of bevacizumab along with a set of chemotherapy drugs.
The study is divided into two stages. The first stage aims to see how many people experience a reduction in tumor size after receiving the treatment. The second stage focuses on observing how long the treatment keeps the cancer from growing or spreading further. Throughout the process, information is gathered to understand how well the medicines work and how they are tolerated by the body.
Austria 
Belgium 
Czechia 
France 
Germany 
Italy 
Poland 
Romania 
Spain 
Sweden 
The Netherlands 